PDF(Pubmed)
Abstract：
BACKGROUND: To evaluate the efficacy of PET/CT using18F-FDG (18F-fluorodeoxyglucose) as a radiotracer compared to conventional bone marrow biopsy (BMB) in detecting infiltration to bone marrow (BM) in pediatric patients with lymphoma at the time of initial diagnosis.
METHODS: 66 pediatric patients with lymphoma (47Hodgkin\'s and 19non-Hodgkin\'s lymphoma) were referred for initial staging by18F-FDG PET/CT study. All patients underwent bilateral iliac BMB and 18F-FDG PET/CT scan with no more than 2 weeks interval in-between. Follow-up for at least 6 months was used as a reference standard to compare diagnostic performance between two modalities in detecting bone marrow infiltration (BMI).
RESULTS: Sensitivity, specificity, accuracy, as well as positive and negative predictive values of 18F-FDG PET/CT in detecting BMI were (80%, 86%, 85%, 63%, and 94%) in contrast to BMB (80%, 53%, 59%, 33%, and 90%) respectively. 18F-FDG PET/CT was concordant to BMB in 39/66 patients (59%).
CONCLUSIONS: 18F-FDG PET/CT was more accurate and specific, with higher predictive values than BMB in detecting BMI during initial staging of pediatric lymphoma. In most pediatric lymphoma patients, 18F-FDG PET/CT can be used instead of BMB to determine BMI during their initial staging process.
METHODS: 66 pediatric patients with lymphoma (47Hodgkin\'s and 19non-Hodgkin\'s lymphoma) were referred for initial staging by18F-FDG PET/CT study. All patients underwent bilateral iliac BMB and 18F-FDG PET/CT scan with no more than 2 weeks interval in-between. Follow-up for at least 6 months was used as a reference standard to compare diagnostic performance between two modalities in detecting bone marrow infiltration (BMI).
RESULTS: Sensitivity, specificity, accuracy, as well as positive and negative predictive values of 18F-FDG PET/CT in detecting BMI were (80%, 86%, 85%, 63%, and 94%) in contrast to BMB (80%, 53%, 59%, 33%, and 90%) respectively. 18F-FDG PET/CT was concordant to BMB in 39/66 patients (59%).
CONCLUSIONS: 18F-FDG PET/CT was more accurate and specific, with higher predictive values than BMB in detecting BMI during initial staging of pediatric lymphoma. In most pediatric lymphoma patients, 18F-FDG PET/CT can be used instead of BMB to determine BMI during their initial staging process.
摘要：
背景：评估PET/CT使用18F-FDG（18F-氟代脱氧葡萄糖）作为放射性示踪剂，与常规骨髓活检（BMB）相比，在首次诊断时检测小儿淋巴瘤患者骨髓浸润（BM）的功效。
方法：66例小儿淋巴瘤患者（47例霍奇金淋巴瘤和19例非霍奇金淋巴瘤）通过18F-FDGPET/CT研究进行初始分期。所有患者均接受双侧BMB和18F-FDGPET/CT扫描，间隔不超过2周。至少6个月的随访被用作参考标准，以比较两种模式在检测骨髓浸润（BMI）方面的诊断性能。
结果：灵敏度，特异性，准确度,以及18F-FDGPET/CT检测BMI的阳性和阴性预测值(80%,86%,85%,63%,和94%)与BMB(80%，53%,59%,33%,和90%)。在39/66例患者中，18F-FDGPET/CT与BMB一致(59%)。
结论：18F-FDGPET/CT更准确、更特异，在儿童淋巴瘤初始分期期间检测BMI的预测值高于BMB。在大多数小儿淋巴瘤患者中，在初始分期过程中，可以使用18F-FDGPET/CT代替BMB来确定BMI。
方法：66例小儿淋巴瘤患者（47例霍奇金淋巴瘤和19例非霍奇金淋巴瘤）通过18F-FDGPET/CT研究进行初始分期。所有患者均接受双侧BMB和18F-FDGPET/CT扫描，间隔不超过2周。至少6个月的随访被用作参考标准，以比较两种模式在检测骨髓浸润（BMI）方面的诊断性能。
结果：灵敏度，特异性，准确度,以及18F-FDGPET/CT检测BMI的阳性和阴性预测值(80%,86%,85%,63%,和94%)与BMB(80%，53%,59%,33%,和90%)。在39/66例患者中，18F-FDGPET/CT与BMB一致(59%)。
结论：18F-FDGPET/CT更准确、更特异，在儿童淋巴瘤初始分期期间检测BMI的预测值高于BMB。在大多数小儿淋巴瘤患者中，在初始分期过程中，可以使用18F-FDGPET/CT代替BMB来确定BMI。
